

? show files

File 10:AGRICOLA 70-2002/Jul

(c) format only 2002 The Dialog Corporation

File 91:MANTIS(TM) 1880-2002/Oct

2001 (c) Action Potential

File 149:TGG Health&Wellness DB(SM) 1976-2002/Jul W1

(c) 2002 The Gale Group

File 164:Allied & Complementary Medicine 1984-2002/Jul

(c) 2002 BLHCIS

File 467:ExtraMED(tm) 2000/Dec

(c) 2001 Informania Ltd.

File 51:Food Sci.&Tech.Abs 1969-2002/Jun W4

(c) 2002 FSTA IFIS Publishing

File 53:FOODLINE(R): Food Science & Technology 1972-2002/Jul 17

(c) 2002 LFRA

File 65:Inside Conferences 1993-2002/Jul W2

(c) 2002 BLDSC all rts. reserv.

File 79:Foods Adlibra(TM) 1974-2002/Apr

(c) 2002 General Mills

? ds

Set	Items	Description
S1	7236	RIBOFLAVIN OR VITAMIN(W) (B2 OR B(W)2)
S2	10067	UREA(W)CYCLE OR ARGININE OR ORNITHINE OR CITRULLINE
S3	7847	ALANINE
S4	24264	GLYCINE
S5	7539	SERINE
S6	1891	TAURINE
S7	4643	THREONINE
S8	3191	VALINE
S9	67	S1 AND S2
S10	42	S9 AND S3-S8
S11	0	S9 AND S3 AND S4 AND S5 AND S6 AND S7 AND S8
S12	194673	CANCER? OR CHEMOTHERAP? OR CHEMO(W)THERAP? OR NEOPLAS?
S13	11598	ENTERAL? OR PARENTERAL?
S16	31	S1(S)S2(S)S3-S8
S17	1	S16(S) (S12 OR S13)

? t s17/7/1

17/7/1 (Item 1 from file: 10)

DIALOG(R)File 10:AGRICOLA

(c) format only 2002 The Dialog Corporation. All rts. reserv.

3665987 20906022 Holding Library: AGL

Flavin-sensitized photooxidation of amino acids present in a parenteral nutrition infusate: protection by ascorbic acid

Garcia, J. Silva, E.

New York, N.Y. : Elsevier Science Inc.

The Journal of nutritional biochemistry. June 1997. v. 8 (6) p. 341-345.

ISSN: 0955-2863 CODEN: JNBIEL

DNAL CALL NO: QP141.A1J54

Language: English

Includes references

Place of Publication: New York

Subfile: IND; OTHER US (NOT EXP STN, EXT, USDA; SINCE 12/76);

Document Type: Article

The visible light mediated photo-oxidation of amino acids present in a \*\*\*\*parenteral\*\*\*\* nutrition infusate was studied, using the sensitizing agents usually included in these solutions: \*\*\*\*riboflavin\*\*\*\*, flavin mononucleotide (FMN), flavin adenine dinucleotide (FAD), and the multivitamin mixture. Of the 14 amino acids studied (\*\*\*\*alanine\*\*\*\*, \*\*\*\*arginine\*\*\*\*, \*\*\*\*glycine\*\*\*\*, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, \*\*\*\*serine\*\*\*\*, \*\*\*\*threonine\*\*\*\*,

tryptophan, and \*\*\*\*valine\*\*\*\*), only histidine, methionine, a tryptophan were photo-oxidized by the action of visible light in the presence of these sensitizers. When a mixture of the three photo-oxidizable amino acids was irradiated the photoconversion of tryptophan predominated. \*\*\*\*Riboflavin\*\*\*\* and FMN had about the same efficiency as sensitizers, whereas FAD was substantially less effective. The photo-oxidative efficiency of the multivitamin infusate on the amino acids, measured on the basis of observed molecular oxygen consumption, was greater significantly than that found in the presence of FMN. This difference is because of the antioxidative effect created by the vitamin C present in the multivitamin infusate, in relation to the pro-oxidative action of the flavin in its excited state. It was found that a solution of ascorbic acid and FMN, whose concentrations were equivalent to the one in a \*\*\*\*parenteral\*\*\*\* nutrition infusate, has the same rate of molecular oxygen consumption as a solution of the multivitamin infusate when irradiated with visible light. The generation of some oxidation products of the tryptophan, generated after irradiation of this amino acid in the presence of FMN, was monitored with emission spectroscopy. On completion of this same experiment, but adding vitamin C, it was observed that for an initial period of time no generation of tryptophan products occurred, after which, tryptophan was modified and had a rate of modification similar to that shown previously. Tryptophan is protected for the time necessary to consume all the vitamin C present in the solution.

=> fil pascal jic caba drugu biosis confsci scisearch  
FILE 'PASCAL' ENTERED AT 16:04:24 ON 17 JUL 2002  
Any reproduction or dissemination in part or in full,  
by means of any process and on any support whatsoever  
is prohibited without the prior written agreement of INIST-CNRS.  
COPYRIGHT (C) 2002 INIST-CNRS. All rights reserved.

FILE 'JICST-EPLUS' ENTERED AT 16:04:24 ON 17 JUL 2002  
COPYRIGHT (C) 2002 Japan Science and Technology Corporation (JST)

FILE 'CABA' ENTERED AT 16:04:24 ON 17 JUL 2002  
COPYRIGHT (C) 2002 CAB INTERNATIONAL (CABI)

FILE 'DRUGU' ENTERED AT 16:04:24 ON 17 JUL 2002  
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'BIOSIS' ENTERED AT 16:04:24 ON 17 JUL 2002  
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'CONFSCI' ENTERED AT 16:04:24 ON 17 JUL 2002  
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'SCISEARCH' ENTERED AT 16:04:24 ON 17 JUL 2002  
COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

=> d que 191; d que 194; fil embase  
L82 18406 SEA RIBOFLAVIN OR VITAMIN(W) (B2 OR B 2)  
L83 3849 SEA UREA CYCLE  
L84 195392 SEA ARGININE OR ORNITHINE OR CITRULLINE  
L85 116492 SEA ALANINE  
L86 192599 SEA GLYCINE  
L87 130439 SEA SERINE  
L88 22636 SEA TAURINE  
L89 51347 SEA THREONINE  
L90 29635 SEA VALINE  
L91 0 SEA L82 AND (L83 OR L84) AND L85 AND L86 AND L87 AND L88 AND  
L89 AND L90

L82 18406 SEA RIBOFLAVIN OR VITAMIN(W) (B2 OR B 2)  
L83 3849 SEA UREA CYCLE  
L84 195392 SEA ARGININE OR ORNITHINE OR CITRULLINE  
L85 116492 SEA ALANINE  
L86 192599 SEA GLYCINE  
L92 62 SEA L82 AND (L83 OR L84) AND (L85 OR L86 OR L87 OR L88 OR L89  
OR L90)  
L93 1601560 SEA CANCER OR CHEMOTHERAP? OR CHEMO THERAP? OR NEOPLAS?  
L94 0 SEA L92 AND L93

FILE 'EMBASE' ENTERED AT 16:04:31 ON 17 JUL 2002  
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE COVERS 1974 TO 11 Jul 2002 (20020711/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

=> d que 181; fil cap1; d que 129;d que 131

L66 3831 SEA FILE=EMBASE ABB=ON RIBOFLAVIN/CT  
L67 9669 SEA FILE=EMBASE ABB=ON ALANINE/CT  
L68 12835 SEA FILE=EMBASE ABB=ON GLYCINE/CT  
L69 8419 SEA FILE=EMBASE ABB=ON SERINE/CT  
L70 5012 SEA FILE=EMBASE ABB=ON TAURINE/CT  
L71 5072 SEA FILE=EMBASE ABB=ON THREONINE/CT  
L72 4580 SEA FILE=EMBASE ABB=ON VALINE/CT  
L73 1586 SEA FILE=EMBASE ABB=ON UREA CYCLE/CT  
L74 18504 SEA FILE=EMBASE ABB=ON ARGININE/CT  
L75 1749 SEA FILE=EMBASE ABB=ON ORNITHINE/CT  
L76 1722 SEA FILE=EMBASE ABB=ON CITRULLINE/CT  
L77 28 SEA FILE=EMBASE ABB=ON L66 AND (L73 OR L74 OR L75 OR L76)  
L80 444218 SEA FILE=EMBASE ABB=ON ORAL DRUG ADMINISTRATION/CT OR  
CANCER/CT  
L81 3 SEA FILE=EMBASE ABB=ON L77 AND (L67 OR L68 OR L69 OR L70 OR  
L71 OR L72) AND L80

FILE 'CAPLUS' ENTERED AT 16:04:41 ON 17 JUL 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Jul 2002 VOL 137 ISS 3  
FILE LAST UPDATED: 16 Jul 2002 (20020716/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

L2 1 SEA FILE=REGISTRY ABB=ON RIBOFLAVIN/CN  
L3 11889 SEA FILE=CAPLUS ABB=ON L2 OR RIBOFLAVIN/OBI  
L5 2 SEA FILE=REGISTRY ABB=ON ALANINE/CN  
L6 1 SEA FILE=REGISTRY ABB=ON GLYCINE/CN  
L7 2 SEA FILE=REGISTRY ABB=ON SERINE/CN  
L8 1 SEA FILE=REGISTRY ABB=ON TAURINE/CN  
L9 2 SEA FILE=REGISTRY ABB=ON THREONINE/CN  
L10 2 SEA FILE=REGISTRY ABB=ON VALINE/CN  
L11 56360 SEA FILE=CAPLUS ABB=ON L5 OR ALANINE/OBI  
L12 71891 SEA FILE=CAPLUS ABB=ON L6 OR GLYCINE/OBI  
L13 44954 SEA FILE=CAPLUS ABB=ON L7 OR SERINE/OBI  
L14 10877 SEA FILE=CAPLUS ABB=ON L8 OR TAURINE/OBI  
L15 26059 SEA FILE=CAPLUS ABB=ON L9 OR THREONINE/OBI  
L16 27861 SEA FILE=CAPLUS ABB=ON L10 OR VALINE/OBI  
L17 2 SEA FILE=REGISTRY ABB=ON ARGININE/CN  
L18 2 SEA FILE=REGISTRY ABB=ON ORNITHINE/CN

L19 1 SEA FILE=REGISTRY ABB=ON CITRULLINE/CN  
L20 46547 SEA FILE=CAPLUS ABB=ON L17 OR ARGININE/OBI  
L21 14776 SEA FILE=CAPLUS ABB=ON L18 OR ORNITHINE/OBI  
L22 3167 SEA FILE=CAPLUS ABB=ON L19 OR CITRULLINE/OBI  
L23 290 SEA FILE=CAPLUS ABB=ON L3 AND (L20 OR L21 OR L22)  
L24 13 SEA FILE=CAPLUS ABB=ON L23 AND L11 AND L12 AND L13 AND L14  
AND L15 AND L16  
L26 10 SEA FILE=CAPLUS ABB=ON L24 AND (17/SC,SX OR 18/SC,SX OR  
FFD/RL)  
L29 8 SEA FILE=CAPLUS ABB=ON L26 NOT (TUNA OR MINKE)/TI

*Section codes*

*17 - Food & Feed  
Chemistry*

*18 - animal nutrition*

L2 1 SEA FILE=REGISTRY ABB=ON RIBOFLAVIN/CN  
L3 11889 SEA FILE=CAPLUS ABB=ON L2 OR RIBOFLAVIN/OBI  
L5 2 SEA FILE=REGISTRY ABB=ON ALANINE/CN  
L6 1 SEA FILE=REGISTRY ABB=ON GLYCINE/CN  
L7 2 SEA FILE=REGISTRY ABB=ON SERINE/CN  
L8 1 SEA FILE=REGISTRY ABB=ON TAURINE/CN  
L9 2 SEA FILE=REGISTRY ABB=ON THREONINE/CN  
L10 2 SEA FILE=REGISTRY ABB=ON VALINE/CN  
~~L11 56360 SEA FILE=CAPLUS ABB=ON L5 OR ALANINE/OBI~~  
L12 71891 SEA FILE=CAPLUS ABB=ON L6 OR GLYCINE/OBI  
L13 44954 SEA FILE=CAPLUS ABB=ON L7 OR SERINE/OBI  
L14 10877 SEA FILE=CAPLUS ABB=ON L8 OR TAURINE/OBI  
L15 26059 SEA FILE=CAPLUS ABB=ON L9 OR THREONINE/OBI  
L16 27861 SEA FILE=CAPLUS ABB=ON L10 OR VALINE/OBI  
L30 579 SEA FILE=CAPLUS ABB=ON UREA CYCLE/CT  
L31 1 SEA FILE=CAPLUS ABB=ON L3 AND L30 AND L11 AND L12 AND L13 AND  
L14 AND L15 AND L16

=> s 129 or 131

L97 8 L29 OR L31

=> fil wpids; d que 144; fil cancer medl; d que 159  
FILE 'WPIDS' ENTERED AT 16:05:00 ON 17 JUL 2002  
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE LAST UPDATED: 11 JUL 2002 <20020711/UP>  
MOST RECENT DERWENT UPDATE 200244 <200244/DW>  
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> The BATCH option for structure searches has been  
enabled in WPINDEX/WPIDS and WPIX >>>

>>> PATENT IMAGES AVAILABLE FOR PRINT AND DISPLAY >>>

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES,  
SEE <http://www.derwent.com/dwpi/updates/dwpcov/index.html> <<<

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,  
PLEASE VISIT:  
[http://www.stn-international.de/training\\_center/patents/stn\\_guide.pdf](http://www.stn-international.de/training_center/patents/stn_guide.pdf) <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER  
GUIDES, PLEASE VISIT:  
[http://www.derwent.com/userguides/dwpi\\_guide.html](http://www.derwent.com/userguides/dwpi_guide.html) <<<

L32 1007 SEA FILE=WPIDS ABB=ON RIBOFLAVIN  
L33 589 SEA FILE=WPIDS ABB=ON VITAMIN(W) (B2 OR B 2)  
L34 43 SEA FILE=WPIDS ABB=ON UREA CYCLE

L35 5491 SEA FILE=WPIDS ABB=ON ARGININE OR ORNITHINE OR CITRULLINE  
L36 6041 SEA FILE=WPIDS ABB=ON ALANINE  
L37 8820 SEA FILE=WPIDS ABB=ON GLYCINE  
L38 5039 SEA FILE=WPIDS ABB=ON SERINE  
L39 1045 SEA FILE=WPIDS ABB=ON TAURINE  
L40 2734 SEA FILE=WPIDS ABB=ON THREONINE  
L41 2647 SEA FILE=WPIDS ABB=ON VALINE  
L43 5 SEA FILE=WPIDS ABB=ON (L32 OR L33) AND (L34 OR L35) AND L36  
AND L37 AND L38 AND L39 AND L40 AND L41  
L44 3 SEA FILE=WPIDS ABB=ON L43 NOT MEDI##/TI

FILE 'CANCERLIT' ENTERED AT 16:05:00 ON 17 JUL 2002

FILE 'MEDLINE' ENTERED AT 16:05:00 ON 17 JUL 2002

L47 3761 SEA RIBOFLAVIN/CT  
L48 13502 SEA ALANINE/CT  
L49 18428 SEA GLYCINE/CT  
L50 11498 SEA SERINE/CT  
L51 5668 SEA TAURINE/CT  
L52 5354 SEA THREONINE/CT  
L53 7217 SEA VALINE/CT  
L54 28944 SEA ARGININE/CT OR ORNITHINE/CT OR CITRULLINE/CT  
L55 1259 SEA UREA CYCLE  
L56 5619 SEA UREA/CT(L) ME/CT *-Subheading ME-metabolism*  
L59 2 SEA L47 AND ((L54 OR L55 OR L56)) AND (L48 OR L49 OR L50 OR  
L51 OR L52 OR L53)

=> dup rem 159,197,181,144

FILE 'MEDLINE' ENTERED AT 16:05:11 ON 17 JUL 2002

FILE 'CAPLUS' ENTERED AT 16:05:11 ON 17 JUL 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 16:05:11 ON 17 JUL 2002

COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'WPIDS' ENTERED AT 16:05:11 ON 17 JUL 2002

COPYRIGHT (C) 2002 THOMSON DERWENT

PROCESSING COMPLETED FOR L59

PROCESSING COMPLETED FOR L97

PROCESSING COMPLETED FOR L81

PROCESSING COMPLETED FOR L44

L98 15 DUP REM L59 L97 L81 L44 (1 DUPLICATE REMOVED)

ANSWERS '1-2' FROM FILE MEDLINE

ANSWERS '3-10' FROM FILE CAPLUS

ANSWERS '11-13' FROM FILE EMBASE

ANSWERS '14-15' FROM FILE WPIDS

=> d ibib ab hitrn 1-15; fil hom

L98 ANSWER 1 OF 15 MEDLINE

ACCESSION NUMBER: 82213478 MEDLINE

DOCUMENT NUMBER: 82213478 PubMed ID: 7085436

TITLE: Nutrition of the cat.

AUTHOR: Brewer N R

SOURCE: JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION,

(1982 May 15) 180 (10) 1179-82.  
Journal code: 7503067. ISSN: 0003-1488.  
PUB. COUNTRY: United States  
Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 198208  
ENTRY DATE: Entered STN: 19900317  
Last Updated on STN: 19900317  
Entered Medline: 19820814

L98 ANSWER 2 OF 15 MEDLINE  
ACCESSION NUMBER: 68006278 MEDLINE  
DOCUMENT NUMBER: 68006278 PubMed ID: 5982344  
TITLE: [Composition of the amino acid pool of Neurospora in  
deficiency of growth substance].  
Zusammensetzung des Aminosäure-Pools von Neurospora im  
Wachstumsstoffmangel.  
AUTHOR: Aurich H  
SOURCE: ACTA BIOLOGICA ET MEDICA GERMANICA, (1966) 16 (2) 123-34.  
Journal code: 0370276. ISSN: 0001-5318.  
PUB. COUNTRY: GERMANY, EAST: German Democratic Republic  
Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: German  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 196712  
ENTRY DATE: Entered STN: 19900101  
Last Updated on STN: 19900101  
Entered Medline: 19671215

L98 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 1  
ACCESSION NUMBER: 2000:706936 CAPLUS  
DOCUMENT NUMBER: 133:265961  
TITLE: Nutraceuticals having N-[N-(3,3-dimethylbutyl)-L-  
.alpha.-aspartyl]-L-phenylalanine 1-methyl ester  
INVENTOR(S): Ponakala, Subbarao V.; Walters, Gale C.; Gerlat, Paula  
A.; Hatchwell, Leora C.  
PATENT ASSIGNEE(S): The Nutrasweet Company, USA  
SOURCE: PCT Int. Appl., 37 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000057726	A1	20001005	WO 2000-US8210	20000329
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 1999-126654P	P 19990329
AB	The present invention provides nutraceuticals comprising N-[N-(3,3-dimethylbutyl)-L-.alpha.-aspartyl]-L-phenylalanine 1-Me ester. This invention also provides nutraceuticals comprising a blend of N-[N-(3,3-dimethylbutyl)-L-.alpha.-aspartyl]-L-phenylalanine 1-Me ester with another sweetener. This invention also provides a method for prepg.			

the nutraceuticals of this invention.

IT 56-40-6, Glycine, biological studies 56-41-7,  
L-Alanine, biological studies 56-45-1, L-  
Serine, biological studies 72-18-4, L-Valine,  
biological studies 72-19-5, L-Threonine, biological  
studies 74-79-3, L-Arginine, biological studies  
83-88-5, Riboflavin, biological studies 107-35-7  
, Taurine

RL: FFD (Food or feed use); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(nutraceuticals having N-[N-(3,3-dimethylbutyl)-L-.alpha.-aspartyl]-L-  
phenylalanine 1-Me ester)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L98 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:409131 CAPLUS

DOCUMENT NUMBER: 136:400997

TITLE: Insulin supplemented infant formula

INVENTOR(S): Shehadeh, Naim

PATENT ASSIGNEE(S): Insotech Ltd., Israel

SOURCE: U.S. Pat. Appl. Publ., 6 pp., Cont.-in-part of U. S.  
Ser. No. 701,652.  
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002064549	A1	20020530	US 2001-15782	20011217
US 6399090	B2	20020604		
WO 9963053	A2	19991209	WO 1999-US12592	19990603
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6365177	B1	20020402	US 2000-701652	20001130

PRIORITY APPLN. INFO.: WO 1999-US12592 W 19990603  
US 2000-701652 A2 20001130  
US 1998-88313P P 19980605  
US 1998-90909 B2 19980605  
WO 1999-US12594 W 19990603

AB An infant formula in a powder or soln. form includes nutritional components and an insulin supplement. A method of feeding an infant includes the steps of dissolving an infant formula powder contg. nutritional components and an insulin supplement in water and feeding the infant with the soln.

IT 56-40-6, Glycine, biological studies 56-41-7,  
L-Alanine, biological studies 56-45-1, L-  
Serine, biological studies 72-18-4, L-Valine,  
biological studies 72-19-5, L-Threonine, biological  
studies 74-79-3, L-Arginine, biological studies  
83-88-5, Vitamin B2, biological studies 107-35-7,  
Taurine

RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)  
(insulin supplemented infant formula)



L98 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:410068 CAPLUS  
DOCUMENT NUMBER: 131:213592  
TITLE: Enhanced nutritive, functional and therapeutic action  
of combined bee products in complex food supplements  
AUTHOR(S): Mateescu, Cristina; Barbulescu, Doina  
CORPORATE SOURCE: Apitherapy Research Department, Institute for  
Apicultural Research & Development, Bucharest, 71544,  
Rom.  
SOURCE: Roumanian Biotechnological Letters (1999), 4(2),  
163-172  
CODEN: RBLEFU; ISSN: 1224-5984  
PUBLISHER: Center for Research in Enzymology and Biotechnology,  
Bucharest University  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Whether pure secretion products (royal jelly) or collected products  
(pollen, propolis, honey), bee products offer the human organism the  
richest spectrum of biochem. compds. with nutritive, functional and  
therapeutic actions. If only vitamins, proteins, enzymes, minerals,  
~~pigments (carotenoids and flavonoids), nucleic acids, complex lipids~~  
(phospholipids), hormone-like substances or hormone precursors, etc., are  
to be mentioned, it is enough to support the choice of these precious  
resources in prepg. complex food supplements, meant to ensure the normal  
function of the human organism. Moreover, many of the above mentioned  
compds. are known for their important anti-oxidative potential, acting  
effectively to prevent the excessive prodn. of free radicals -  
incriminated for the occurrence of several functional disturbances and  
even of pathol. processes. Based on studies of the biochem. compn. of the  
bee products and on their already proven action in several clin. trials,  
some formulas of balanced nutritive-functional supplements were developed.  
Beside bee products - royal jelly, pollen or pollen exts., propolis - as  
soft (spiss) ext. and honey - plant lecithin, mineral salts (calcium,  
phosphorous, potassium), and an extra supply of vitamin C were used to  
potentiate their actions. These food supplements are esp. designated to  
regulate the metabolic processes in both healthy organisms and those  
affected by several deficiencies generated by pathol. processes or  
suffering the effects of special environmental and working conditions.

IT 56-40-6, **Glycine**, biological studies 56-41-7,  
L-Alanine, biological studies 56-45-1, L-  
Serine, biological studies 70-26-8, L-Ornithine  
72-18-4, L-Valine, biological studies 72-19-5,  
L-Threonine, biological studies 74-79-3, L-  
Arginine, biological studies 83-88-5, Riboflavin  
, biological studies 107-35-7, Taurine  
372-75-8, Citrulline

RL: BOC (Biological occurrence); BSU (Biological study, unclassified);

BIOL (Biological study); OCCU (Occurrence)

(enhanced nutritive, functional and therapeutic action of combined bee  
products in complex food supplements)

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L98 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1997:42018 CAPLUS  
DOCUMENT NUMBER: 126:65460  
TITLE: Enteral composition for treating renal failure  
INVENTOR(S): Chang, Shen-Youn; Madsen, Dave C.; Trimbo, Susan L.;  
Tucker, Hugh N.; Twyman, Diana  
PATENT ASSIGNEE(S): Clintec Nutrition Company, An Illinois Partnership,  
USA  
SOURCE: Eur. Pat. Appl., 8 pp.

DOCUMENT TYPE: CODEN: EPXXDW  
Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 747395	A1	19961211	EP 1996-201536	19960604
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
US 5728678	A	19980317	US 1995-470985	19950606
CA 2177195	AA	19961207	CA 1996-2177195	19960523
JP 09020678	A2	19970121	JP 1996-141368	19960604

PRIORITY APPLN. INFO.: US 1995-470985 19950606

AB The invention provides an enteral compn. for providing nutrition to renal patients. The enteral compn. includes an effective amt. of a protein source including whey protein and free amino acids that provide essential as well as nonessential amino acids. The compn. is calorically dense and has a moderate osmolality.

IT **56-40-6, Glycine**, biological studies **56-41-7, L-Alanine**, biological studies **56-45-1, L-Serine**, biological studies **72-18-4, L-Valine**, biological studies **72-19-5, L-Threonine**, biological studies **74-79-3, L-Arginine**, biological studies **83-88-5, Vitamin B2**, biological studies **107-35-7, Taurine**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(enteral compn. for renal failure)

L98 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1996:254681 CAPLUS

DOCUMENT NUMBER: 124:287735

TITLE: Adolescent dietary composition containing an optimal amino acid content

INVENTOR(S): Lowry, Carol J.; Schmidl, Mary K.

PATENT ASSIGNEE(S): Sandoz Nutrition Ltd., Switz.

SOURCE: Eur. Pat. Appl., 24 pp.  
CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 705542	A1	19960410	EP 1995-810580	19950919
EP 705542	B1	19971229		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
US 5719133	A	19980217	US 1994-309815	19940921
CA 2158635	AA	19960322	CA 1995-2158635	19950919
CA 2158635	C	19980512		
AT 161397	E	19980115	AT 1995-810580	19950919
ES 2111384	T3	19980301	ES 1995-810580	19950919
TW 410160	B	20001101	TW 1995-84110289	19951003
US 5719134	A	19980217	US 1996-715298	19960917

PRIORITY APPLN. INFO.: US 1994-309815 A 19940921

AB A dietary compn. for oral or enteral administration to a human adolescent is described which comprises (a) a carbohydrate component which comprises 50-65% of the total caloric content of said compn.; (b) a lipid component which comprises 20-35% of the total caloric content of said compn.; and (c) an amino acid component which comprises 10-20% of the total caloric content of said compn. and which comprises 2.3-2.8 L-histidine, 6.1-7.4% L-isoleucine, 8.5-10.2% L-leucine, 7.0-8.4% L-valine, 6.6-8.0% L-lysine,

3.1-3.8% L-methionine, 5.5-6.6% L-phenylalanine, 4.8-5.8% L-threonine, 1.7-2.1% L-tryptophan, 5.7-6.9% L-alanine, 6.2-7.5% L-arginine, 5.9-7.1% L-aspartic acid, 2.3-2.8% L-cystine, 12.9-15.5% L-glutamine, 3.8-4.6% L-glutamic acid, 3.2-3.9% glycine, 5.0-6.0% L-proline, 5.4-6.5% L-serine, and 4.0-4.8% L-tyrosine, all based on total wt. of said amino acid component. The compn. is particularly useful for adolescents who are undergoing certain conditions or disease, and who are unable to consume food orally and must be fed enterally. The compn. provides the optimal osmolality and amt. of amino acids and other components required for growth.

IT 56-40-6, **Glycine**, biological studies 56-41-7, **Alanine**, biological studies 56-45-1, **L-Serine**, biological studies 72-18-4, **Valine**, biological studies 72-19-5, **Threonine**, biological studies 74-79-3, **Arginine**, biological studies 83-88-5, **Riboflavine**, biological studies 107-35-7, **Taurine**  
RL: BOC (Biological occurrence); **FFD (Food or feed use)**; BIOL (Biological study); OCCU (Occurrence); USES (Uses)  
(human adolescent dietary compn. contg. an optimal amino acid content)

L98 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1996:548447 CAPLUS  
DOCUMENT NUMBER: 125:194355  
TITLE: Nutritional composition containing improved dietary nitrogen component  
INVENTOR(S): Hahn, Douglas E.; Schmidl, Mary Kathrine  
PATENT ASSIGNEE(S): USA  
SOURCE: Can. Pat. Appl., 26 pp.  
CODEN: CPXXEB  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2163379	AA	19960524	CA 1995-2163379	19951121

PRIORITY APPLN. INFO.: US 1994-344903 19941123

AB Liq. nutritional compn. comprising, based on total caloric content, from 60 to 75% carbohydrate component, 10 to 20% lipid component and 15 to 25% dietary nitrogen component, wherein the dietary nitrogen component comprises from 20 to 30% by wt. free amino acids, 60 to 75% by wt. hydrolyzed casein and 5 to 15% by wt. intact caseinate protein based on total wt. of the dietary nitrogen component is disclosed.

IT 56-40-6, **Glycine**, biological studies 56-41-7, **L-Alanine**, biological studies 56-45-1, **L-Serine**, biological studies 72-18-4, **L-Valine**, biological studies 72-19-5, **L-Threonine**, biological studies 74-79-3, **L-Arginine**, biological studies 83-88-5, **Riboflavin**, biological studies 107-35-7, **Taurine**  
RL: BAC (Biological activity or effector, except adverse); **FFD (Food or feed use)**; BIOL (Biological study); USES (Uses)  
(nutritional compn. contg. improved dietary nitrogen component)

L98 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1994:541707 CAPLUS  
DOCUMENT NUMBER: 121:141707  
TITLE: Medical foods for the nutritional support of infant/toddler metabolic diseases  
INVENTOR(S): Acosta, Phyllis Jean Brown; Grondalski, Richard Andrew; Liebrecht, Jeffrey Wayne; Reynolds, Patricia Ann

PATENT ASSIGNEE(S): Abbott Laboratories, USA  
SOURCE: PCT Int. Appl., 47 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9414458	A1	19940707	WO 1993-US10866	19931110
W: AU, CA, JP, KR, NZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9455991	A1	19940719	AU 1994-55991	19931110
AU 679020	B2	19970619		
EP 675725	A1	19951011	EP 1994-901392	19931110
EP 675725	B1	20020130		
R: DE, ES, FR, GB, IE, IT, NL				
CA 2143420	C	19990119	CA 1993-2143420	19931110
US 5587399	A	19961224	US 1994-230452	19940420
US 5550146	A	19960827	US 1995-423177	19950418
PRIORITY APPLN. INFO.:			US 1992-997278	A 19921223
			WO 1993-US10866	W 19931110
			US 1994-230452	A3 19940420
AB	A novel generic powder base rich in fats, carbohydrates, vitamins, minerals and trace elements is readily admixed with specific amino acids to yield several different therapeutic products for use in nutritional support of infant/toddlers having various inherited metabolic diseases.			
IT	<b>56-40-6, Glycine</b> , biological studies <b>56-41-7, Alanine</b> , biological studies <b>56-45-1, Serine</b> , biological studies <b>72-18-4, Valine</b> , biological studies <b>72-19-5, Threonine</b> , biological studies <b>74-79-3, Arginine</b> , biological studies RL: BIOL (Biological study) (nutritional compns. contg., for infants and toddlers with metabolic diseases)			
IT	<b>83-88-5, Vitamin B2</b> , biological studies <b>107-35-7, Taurine</b> RL: BIOL (Biological study) (nutritional premix. compns. contg., for infants and toddlers with metabolic diseases)			
L98 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2002 ACS				
ACCESSION NUMBER:		1988:487973 CAPLUS		
DOCUMENT NUMBER:		109:87973		
TITLE:		Influence of additional vitaminization on free amino acids of the liver and brain in rats with alcohol poisoning		
AUTHOR(S):		Ostrovskii, S. Yu.; Grinevich, V. P.		
CORPORATE SOURCE:		Inst. Biokhim., Grodno, USSR		
SOURCE:		Vopr. Pitan. (1988), (3), 41-5 CODEN: VPITAR; ISSN: 0042-8833		
DOCUMENT TYPE:		Journal		
LANGUAGE:		Russian		
AB	Combined action was studied of ethanol, pyridoxine (3 mg/kg), and a mixt. of thiamine (5 mg/kg), riboflavin (5 mg/kg), pyridoxine (3 mg/kg) and pantothenate (15 mg/kg) on free amino acid concns. in the brain and liver of rats. Ethanol was given to the animals with a liq. semisynthetic diet during 30 days. Both pyridoxine and the complex of vitamin B group normalized the compn. of the free amino acid pool by correcting the shifts induced by ethanol. Thus, the vitamin treatment moderates or normalizes the amino acid changes esp. in central nervous system.			
IT	<b>83-88-5, Riboflavin</b> , biological studies			

RL: BIOL (Biological study)  
(free amino acids of brain and liver in ethanol poisoning response to)  
IT 56-40-6, **Glycine**, biological studies 56-41-7,  
**Alanine**, biological studies 56-45-1, **Serine**,  
biological studies 70-26-8, **Ornithine** 72-18-4  
, **Valine**, biological studies 72-19-5,  
**Threonine**, biological studies 74-79-3, **Arginine**  
, biological studies 107-35-7, **Taurine**  
RL: BIOL (Biological study)  
(of brain and liver, in ethanol poisoning, vitamins effect on)

L98 ANSWER 11 OF 15 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
ACCESSION NUMBER: 87041058 EMBASE  
DOCUMENT NUMBER: 1987041058  
TITLE: [Organic acidemias and urea cycle defects: Diagnosis and  
new therapeutical trends].  
ACADEMIE ORGANICHE E DIFETTI DEL CICLO DELL'UREA:  
INQUADRAMENTO DIAGNOSTICO E NUOVE PROSPETTIVE TERAPEUTICHE.  
AUTHOR: Sabetta G.; Gambarara M.; Dionisi Vici C.; et al.  
CORPORATE SOURCE: Servizio di Patologia Metabolica, Ospedale Pediatrico  
Bambino Gesù, Istituto di Ricerca Scientifica, Roma, Italy  
-----SOURCE: ----- Rivista Italiana di Pediatria, (1986) 12/5 (486-491).-----  
CODEN: RITODB  
COUNTRY: Italy  
DOCUMENT TYPE: Journal  
FILE SEGMENT: 037 Drug Literature Index  
LANGUAGE: Italian  
SUMMARY LANGUAGE: English

L98 ANSWER 12 OF 15 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
ACCESSION NUMBER: 85030858 EMBASE  
DOCUMENT NUMBER: 1985030858  
TITLE: Nutrients and cancer: An introduction to cesium therapy.  
AUTHOR: Sartori H.E.  
CORPORATE SOURCE: Life Science Universal Medical Center, Washington, DC  
20008, United States  
SOURCE: Pharmacology Biochemistry and Behavior, (1984) 21/SUPPL. 1  
(7-10).  
CODEN: PBBHAU  
COUNTRY: United States  
DOCUMENT TYPE: Journal  
FILE SEGMENT: 037 Drug Literature Index  
030 Pharmacology  
017 Public Health, Social Medicine and Epidemiology  
016 Cancer  
LANGUAGE: English

AB A brief overview on the relevance in dietary factors in both development  
and prevention of cancer is presented. The pharmacologic properties of  
various food ingredients are discussed. Establishing of a special diet for  
the cancer patient is suggested. In addition, avoidance of certain foods  
is recommended to counteract mucus production of cancer cells. Evaluation  
of the nutrient content of certain diets in regions with low incidence of  
cancer has advanced the use of certain alkali metals, i.e., rubidium and  
cesium, as chemotherapeutic agents. The rationale for this approach termed  
the 'high pH' therapy resides in changing the acidic pH range of the  
cancer cell by cesium towards weak alkalinity in which the survival of the  
cancer cell is endangered, and the formation of acidic and toxic  
materials, normally formed in cancer cells, is neutralized and eliminated.

L98 ANSWER 13 OF 15 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
ACCESSION NUMBER: 77054556 EMBASE  
DOCUMENT NUMBER: 1977054556  
TITLE: [Effects of arginine in the treatment of male infertility].  
-----

UBER DIE WIRKUNGEN VON ARGININ BEI DER BEHANDLUNG VON  
FERTILITATSSTORUNGEN DES MANNES.  
AUTHOR: Da Rugna D.; Stahel Th.  
CORPORATE SOURCE: Univ. Frauenklin., Kantonsspit. Basel, Switzerland  
SOURCE: Praxis, (1976) 65/16 (481-485).  
CODEN: PRAXAF  
DOCUMENT TYPE: Journal  
FILE SEGMENT: 037 Drug Literature Index  
LANGUAGE: German

L98 ANSWER 14 OF 15 WPIDS (C) 2002 THOMSON DERWENT  
ACCESSION NUMBER: 2002-415383 [44] WPIDS  
DOC. NO. NON-CPI: N2002-326759  
DOC. NO. CPI: C2002-117233  
TITLE: Composition useful in the treatment of obesity comprises  
at least one micronutrient and target absorbent compound.  
DERWENT CLASS: B04 D13 J04 S03  
INVENTOR(S): BUCHANAN-BAILLIE-HAMILTON, P F; PECK, J C  
PATENT ASSIGNEE(S): (BUCH-I) BUCHANAN-BAILLIE-HAMILTON P F  
COUNTRY COUNT: 96  
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2002012882	A2	20020214	(200244)*	EN	86
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW					
AU 2001076537	A	20020218	(200244)		

## APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2002012882	A2	WO 2001-GB3554	20010807
AU 2001076537	A	AU 2001-76537	20010807

## FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2001076537	A Based on	WO 200212882

PRIORITY APPLN. INFO: GB 2001-17052 20010712; GB 2000-19327  
20000808

AB WO 200212882 A UPAB: 20020711

NOVELTY - A composition comprises at least one active compound e.g.  
micronutrient or target compound absorbent.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the  
following: 1) a method for comparing the relative inhibitory effects of  
several of target compounds (A1)/items on the ability of a test subject  
(A2)/(A2) exposed to the items to control their weight involving  
performing the method for each (A1)/item, and comparing the inhibitory  
effects of each (A1)/item; 2) a method for labeling and/or certifying an  
item according to its inhibitory effect on the ability of (A2) exposed to  
the item to control their weight involving performing the method for the  
item, and labeling and/or certifying the item based on a pre-determined  
scale according to their inhibitory effect; 3) a method of diagnosis  
and/or prognosis of a weight-control-related disorder or disease in (A2)  
involving performing a method and correlating the results obtained from

the method with the disease state of the subject; 4) determining a test subject's progress in altering the extent to which their ability to control their weight has been inhibited involving performing the method at intervals, and comparing the results obtained from the method to establish the progress made; 5) production of a tailored advice plan for (A2) involving performing a method and providing a plan in accordance with the results obtained from the method. The plan provides a system for improving or maintaining the ability of (A2) to control their weight; 6) determining the extent of the inhibitory effect of (A1) on the ability of (A2) into whom (A1) is introduced to control their weight involving (i) determining the degree or severity by which (A1) affects each of several weight controlling systems (HICS) present in (A2); (ii) determining the persistence of (A1) in (A2); (iii) calculating the inhibitory effect as a function of values of (i) and (ii); 7) Use of the composition in the preparation of a medicament for the treatment of obesity; 8) production of a database of the inhibitory effects of several (A1)/items on the ability of (A2)/(A2) exposed to the items to control their weight involving performing the method for each (A1)/items, and combining the results into a database; 9) computer system for use in the performance of a method or displaying the output of the method, or displaying or accessing the database, comprising (a) a standard electronic computer circuit containing at least a random access memory, a read only memory, a processor; (b) a keyboard comprising several standard keyboard buttons; and (c) a display; 11) production of a labeled and/or certified item, involving providing the item to be labeled and/or certified, and performing the method on the item; 12) a database produced by the method; 13) a data carrier comprising the database; 14) determining the inhibitory effect of an item on the ability of (A2) exposed to the item to control their weight involving: a) optionally determining the amount of each of several (A1) in the item having an inhibitory effect on the ability of (A2) to control their weight; and 15) a system for improving or maintaining the ability of (A2) to control their weight including (a) a commodity provider, which provides commodities for (A2), (b) a certifier which certifies each commodity according to its inhibitory effect on the ability of (A2) exposed to the item to control their weight such that the subject can select each commodity to its certification. The certifier optionally uses an analyzer for determining the presence of (A1) in each commodity and a database of the inhibitory effect of (A1) present in the commodity on the ability of (A2) to control their weight.

ACTIVITY - Anorectic; Cardiant; Antiasthmatic; Antiallergic; Cytostatic; Dermatological; Immunosuppressive.

MECHANISM OF ACTION - Inhibitor.

USE - For cosmetic improvement of the subject, which does not suffer from obesity; for treatment of the subject suffering from obesity; for use in a method for treatment of obesity; for controlling the weight of the subject; in the preparation of the medicament for the treatment of obesity (all claimed); for the control and treatment of various conditions associated with obesity e.g. immune dysfunction, autoimmunity, cardiovascular disorder, pulmonary disorder (e.g. asthma), allergies, cancer, mood changes, neurological illness, changes in libido, hormonal disorders, reproductive dysfunction, congenital abnormalities, metabolic disorder (e.g. glucose dysregulation), muscular skeletal disorder, renal and genitourinary disorder and skin disorder.

ADVANTAGE - The composition achieves significantly more effective and long lasting weight reduction without the use of drugs which interferes with the body's natural metabolism, by means of effectively restoring the body's own natural slimming system in a substantially natural manner.  
Dwg.0/9

L98 ANSWER 15 OF 15 WPIDS (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: 1999-550826 [46] WPIDS

DOC. NO. CPI: C1999-160620

TITLE: A composition comprising one or more hormone(s), amino

acid(s), enzyme(s) and/or vitamin(s) and mineral (s) for treatment of the human body - used to treat cardiovascular, autoimmune diseases and Parkinson's disease.

DERWENT CLASS: B05  
 INVENTOR(S): COCHRAN, T M; COCHRAN, T  
 PATENT ASSIGNEE(S): (COCH-I) COCHRAN T; (COCH-I) COCHRAN T M  
 COUNTRY COUNT: 85  
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9943329	A1	19990902	(199946)*	EN	54
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ UG ZW					
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW					
AU 9927901	A	19990915	(200004)		
US 6048846	A	20000411	(200025)		
EP 1146878	A1	20011024	(200171)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					

## APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9943329	A1	WO 1999-US4130	19990225
AU 9927901	A	AU 1999-27901	19990225
US 6048846	A	US 1998-31227	19980226
EP 1146878	A1	EP 1999-908474	19990225
		WO 1999-US4130	19990225

## FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9927901	A Based on	WO 9943329
EP 1146878	A1 Based on	WO 9943329

PRIORITY APPLN. INFO: US 1998-31227 19980226

AB WO 9943329 A UPAB: 19991110

NOVELTY - A composition for treating the human body comprises at least one hormone, amino acid, enzyme and/or vitamin and at least one mineral with relative proportions such that they are balanced with respect to each other for restoring optimal levels in the body and also operating synergistically to provide nutrients and command/regulatory components enabling the body to effectively utilize them.

USE - The composition is used to restore levels of hormone, amino acid, enzyme and mineral to the optimum in the body to maintain the health of the body and fight disease. The composition is useful for treating cardiovascular diseases, autoimmune diseases, Parkinson's disease etc. The composition may also prove to be useful in the treatment of Lupus and Fibromyalgia syndrome, chronic fatigue syndrome and rheumatoid arthritis.  
 Dwg.0/8

FILE 'HOME' ENTERED AT 16:05:28 ON 17 JUL 2002